Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes

项目摘要 该项目利用翻译的方法，使用新的测定，以了解耐药性的出现， 治疗结核病（TB）病原体结核分枝杆菌（Mtb）的药物。耐药结核病 在过去的15年中，全球发病率增加了80%，死亡率高，治疗过程延长， 和糟糕的结果。全球耐多药结核病（MDR-TB）治愈率平均为65%， 耐多药结核病患者在接受治疗时出现耐药性扩大。虽然紧急耐药性是一个 重大挑战往往发现得太晚。该应用程序将研究来自患者的成对Mtb菌株， 在基线时对药物敏感的结核病然后发展为耐药结核病。有广泛的临床和依从性 这些患者的数据。将进行耐药机制的功能测定，以更好地了解 在治疗过程中产生耐药性。

Project Summary This project utilizes translational approaches to use novel assays to understand the emergence of resistance to drugs to treat Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). Drug-resistant TB incidence has increased 80% worldwide over the past 15 years with high mortality, prolonged treatment course, and poor outcomes. Global multi-drug resistant TB (MDR-TB) cure rates average 65% and as many as 11% of MDR-TB patients develop amplification of drug-resistance on treatment. While emergent drug-resistance is a major challenge it is often detected too late. This application will study pairs of Mtb strains from patients that had drug-susceptible TB at baseline then developed drug-resistant TB. There is extensive clinical and adherence data for these patients. Functional assays for drug-resistance mechanisms will be done to better understand development of drug-resistance under treatment.